Barrett's to oesophageal cancer sequence: A model of inflammatory-driven upper gastrointestinal cancer

Digestive Surgery

Volumn 29, Issue 3, 2012, Pages 251-260

  Picardo, Sarah L ^a   Maher, Stephen G ^a   O'Sullivan, Jacintha N ^a   Reynolds, John V ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Barrett's oesophagus; Inflammation; Microenvironment; Oesophageal adenocarcinoma

Indexed keywords

CYTOKINE; SIGNAL PEPTIDE;

ADENOCARCINOMA; ANOXIA; ARTICLE; BARRETT ESOPHAGUS; CELL TRANSFORMATION; ESOPHAGUS TUMOR; EXTRACELLULAR MATRIX; HUMAN; IMMUNOLOGY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; PRECANCER; REFLUX ESOPHAGITIS; T LYMPHOCYTE; VASCULARIZATION;

ADENOCARCINOMA; ANOXIA; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS, PEPTIC; EXTRACELLULAR MATRIX; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; PRECANCEROUS CONDITIONS; T-LYMPHOCYTES;

EID: 84864526455     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000341498     Document Type: Article

References (101)

1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57-70.
2. Allen M, Louise Jones J: Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 2011;223:162-176.
3. Gribben J, Rosenwald A, Gascoyne R, Lenz G: Targeting the microenvironment. Leuk Lymphoma 2010;51(suppl 1):34-40.
4. Holmes RS, Vaughan TL: Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007;17:2-9.
5. Pohl H, Welch HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-146.
6. Wild CP, Hardie LJ: Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer 2003;3:676-684.
7. Corley DA, Kerlikowske K, Verma R, Buffler P: Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003;124:47-56.
8. Sadeghi S, Bain CJ, Pandeya N, Webb PM, Green AC, et al: Aspirin, nonsteroidal antiinflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev 2008;17:1169-1178.
9. Wang F, Lv ZS, Fu YK: Nonsteroidal anti-inflammatory drugs and esophageal inflammation-Barrett's esophagus-adenocarcinoma sequence: a meta-analysis. Dis Esophagus 2010.
10. Bobryshev YV, Tran D, Killingsworth MC, Buckland M, Lord RV: Dendritic cell-associated immune inflammation of cardiac mucosa: a possible factor in the formation of Barrett's esophagus. J Gastrointest Surg 2009; 13:442-450.
11. Bobryshev YV, Tran D, Killingsworth MC, Buckland M, Lord RV: Dendritic cells in Barrett's esophagus and esophageal ad-enocarcinoma. J Gastrointest Surg 2009;13: 44-53.
12. Bobryshev YV, Freeman AK, Botelho NK, Tran D, Levert-Mignon AJ, et al: Expression of the putative stem cell marker Musashi-1 in Barrett's esophagus and esophageal ad-enocarcinoma. Dis Esophagus 2010;23: 580-589.
13. Berndt U, Philipsen L, Bartsch S, Hu Y, Rocken C, et al: Comparative multi-epit-ope-ligand-cartography reveals essential immunological alterations in Barrett's metaplasia and esophageal adenocarcinoma. Mol Cancer 2010;9:177.
14. Schumacher K, Haensch W, Roefzaad C, Schlag PM: Prognostic significance of activated CD8+ T-cell infiltrations within esophageal carcinomas. Cancer Res 2001;61: 3932-3936.
15. Zingg U, Montani M, Frey DM, Dirnhofer S, Esterman AJ, et al: Tumour-infiltrating lymphocytes and survival in patients with ad-enocarcinoma of the oesophagus. Eur J Surg Oncol 2010;36:670-677.
16. Moons LM, Kusters JG, Bultman E, Kuipers EJ, van Dekken H, et al: Barrett's oesophagus is characterized by a predominantly humoral inflammatory response. J Pathol 2005;207: 269-276.
17. Ravi K, Katzka DA, Smyrk TC, Prasad GA, Romero Y, et al: Prevalence of esophageal eosinophils in patients with Barrett's esophagus. Am J Gastroenterol 2011;106:851-857.
18. McDonnell CO, Bouchier-Hayes DJ, Toomey D, Foley D, Kay EW, et al: Effect of neoadjuvant chemoradiotherapy on angio-genesis in oesophageal cancer. Br J Surg 2003; 90:1373-1378.
19. Salmela MT, Karjalainen-Lindsberg ML, Puolakkainen P, Saarialho-Kere U: Upregulation and differential expression of matrily-sin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma. Br J Cancer 2001;85:383-392.
20. Nguyen GH, Schetter AJ, Chou DB, Bowman ED, Zhao R, et al: Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma. Clin Cancer Res 2010;16: 5824-5834.
21. Zhang HY, Zhang Q, Zhang X, Yu C, Huo X, et al: Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells. Am J Physiol Gastrointest Liver Physiol 2011;300: G454-G460.
22. Dvorak K, Chavarria M, Payne CM, Ramsey L, Crowley-Weber C, et al: Activation of the interleukin-6/STAT3 antiapoptotic pathway in esophageal cells by bile acids and low pH: relevance to Barrett's esophagus. Clin Cancer Res 2007;13:5305-5313.
23. Dvorakova K, Payne CM, Ramsey L, Holubec H, Sampliner R, et al: Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus. Clin Cancer Res 2004;10:2020-2028.
24. Wei LH, Kuo ML, Chen CA, Chou CH, Cheng WF, et al: The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene 2001;20: 5799-5809.
25. Lin MT, Juan CY, Chang KJ, Chen WJ, Kuo ML: IL-6 inhibits apoptosis and retains oxi-dative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1. Carcinogenesis 2001; 22:1947-1953.
26. Hong S, Lee HJ, Kim SJ, Hahm KB: Connection between inflammation and carcinogenesis in gastrointestinal tract: focus on TGF-fS signaling. World J Gastroenterol 2010; 16:2080-2093.
27. 1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis. Mol Carcinog 2006;45:786-794.
28. Onwuegbusi BA, Rees JR, Lao-Sirieix P, Fitzgerald RC: Selective loss of TGF-(3 Smad-dependent signalling prevents cell cycle arrest and promotes invasion in oesophageal adenocarcinoma cell lines. PLoS One 2007;2: e177.
29. Rees JR, Onwuegbusi BA, Save VE, Alderson D, Fitzgerald RC: In vivo and in vitro evidence for transforming growth factor-pV mediated epithelial to mesenchymal transition in esophageal adenocarcinoma. Cancer Res 2006;66:9583-9590.
30. Saadi A, Shannon NB, Lao-Sirieix P, O'Donovan M, Walker E, et al: Stromal genes discriminate preinvasive from invasive disease, predict outcome, and high-light inflammatory pathways in digestive cancers. Proc Natl Acad Sci USA 2010;107: 2177-2182.
31. Kuramochi H, Vallbohmer D, Uchida K, Schneider S, Hamoui N, et al: Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma. J Gastrointest Surg 2004;8:1007-1016.
32. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE: Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001;96:990-996.
33. Lagorce C, Paraf F, Vidaud D, Couvelard A, Wendum D, et al: Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma. Histopathology 2003;42:457-465.
34. France M, Drew PA, Dodd T, Watson DI: Cyclo-oxygenase-2 expression in esophageal adenocarcinoma as a determinant of clinical outcome following esophagectomy. Dis Esophagus 2004;17:136-140.
35. Jenkins GJ, Mikhail J, Alhamdani A, Brown TH, Caplin S, et al: Immunohistochemical study of nuclear factor-KB activity and interleukin-8 abundance in oesophageal adeno-carcinoma; a useful strategy for monitoring these biomarkers. J Clin Pathol 2007;60: 1232-1237.
36. O'Riordan JM, Abdel-Latif MM, Ravi N, McNamara D, Byrne PJ, et al: Proinflam-matory cytokine and nuclear factor KB expression along the inflammation-meta-plasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol 2005; 100:1257-1264.
37. Jenkins GJ, Harries K, Doak SH, Wilmes A, Griffiths AP, et al: The bile acid deoxycho-lic acid at neutral pH activates NF-KB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis 2004;25:317-323.
38. Duggan SP, Gallagher WM, Fox EJ, Ab-del-Latif MM, Reynolds JV, et al: Low pH induces coordinate regulation of gene expression in oesophageal cells. Carcinogenesis 2006;27:319-327.
39. Abdel-Latif MM, O'Riordan J, Windle HJ, Carton E, Ravi N, et al: NF-KB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 2004;239:491-500.
40. Fitzgerald RC, Abdalla S, Onwuegbusi BA, Sirieix P, Saeed IT, et al: Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 2002;51: 316-322.
41. Konturek PC, Burnat G, Rau T, Hahn EG, Konturek S: Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line. Dig Dis Sci 2008;53:597-605.
42. Lysaght J, Allott EH, Donohoe CL, Howard JM, Pidgeon GP, et al: T lymphocyte activation in visceral adipose tissue of patients with oesophageal adenocarcinoma. Br J Surg 2011;98:964-974.
43. Tai IT, Tang MJ: SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat 2008;11: 231-246.
44. Botelho NK, Schneiders FI, Lord SJ, Freeman AK, Tyagi S, et al: Gene expression alterations in formalin-fixed, paraffin-embedded Barrett esophagus and esophageal adenocar-cinoma tissues. Cancer Biol Ther 2010;10: 172-179.
45. Brabender J, Marjoram P, Lord RV, Metzger R, Salonga D, et al: The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2005;14: 2113-2117.
46. Brabender J, Lord RV, Metzger R, Park J, Sa-longa D, et al: Differential SPARC mRNA expression in Barrett's oesophagus. Br J Cancer 2003;89:1508-1512.
47. Rojas A, Meherem S, Kim YH, Washington MK, Willis JE, et al: The aberrant methyla-tion of TSP1 suppresses TGF-p^ activation in colorectal cancer. Int J Cancer 2008;123: 14-21.
48. Miller CT, Lin L, Casper AM, Lim J, Thomas DG, et al: Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esoph-ageal adenocarcinoma. Oncogene 2006;25: 409-418.
49. Grimm M, Lazariotou M, Kircher S, Stuermer L, Reiber C, et al: MMP-1 is a (pre-)invasive factor in Barrett-associated esophageal adenocarcinomas and is associated with positive lymph node status. J Transl Med 2010; 8:99.
50. Keld R, Guo B, Downey P, Gulmann C, Ang YS, et al: The ERK MAP kinase-PEA3/ETV4-MMP-1 axis is operative in oesopha-geal adenocarcinoma. Mol Cancer 2010;9: 313.
51. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, et al: Matrix metallopro-teinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998;185: 256-261.
52. Herszenyi L, Hritz I, Pregun I, Sipos F, Juhasz M, et al: Alterations of glutathione S- transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis. World J Gastroenterol 2007; 13:676-682.
53. Lagarde SM, ten Kate FJ, Richel DJ, Offerhaus GJ, van Lanschot JJ: Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 2007;14:977-991.
54. Auvinen MI, Sihvo EI, Ruohtula T, Salminen JT, Koivistoinen A, et al: Incipient angiogen-esis in Barrett's epithelium and lymphan-giogenesis in Barrett's adenocarcinoma. J Clin Oncol 2002;20:2971-2979.
55. Mroczko B, Kozlowski M, Groblewska M, Lukaszewicz M, Niklinski J, et al: Expression of matrix metalloproteinase-9 in the neoplastic and interstitial inflammatory infiltrate cells in the different histopathological types of esophageal cancer. Folia Histochem Cytobiol 2008;46:471-478.
56. Ogunwobi OO, Beales IL: Leptin stimulates the proliferation of human oesophageal ad-enocarcinoma cells via HB-EGF and TGF-a mediated transactivation of the epidermal growth factor receptor. Br J Biomed Sci 2008; 65:121-127.
57. Heath EI, Burtness BA, Kleinberg L, Salem RR, Yang SC, et al: Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease inhibitor prinomastat in patients with esopha-geal adenocarcinoma. Invest New Drugs 2006;24:135-140.
58. Ling FC, Khochfar J, Baldus SE, Brabender J, Drebber U, et al: HIF-lalpha protein expression is associated with the environmental inflammatory reaction in Barrett's metaplasia. Dis Esophagus 2009;22:694-699.
59. Griffiths EA, Pritchard SA, McGrath SM, Valentine HR, Price PM, et al: Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adeno-carcinoma sequence. Br J Cancer 2007;96: 1377-1383.
60. Von Holzen U, Chen T, Boquoi A, Richter JE, Falk GW, et al: Evidence for DNA damage checkpoint activation in Barrett esophagus. Transl Oncol 2010;3:33-42.
61. Kaye PV, Haider SA, Ilyas M, James PD, Soomro I, et al: Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry. Histopathology 2009;54:699-712.
62. Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, et al: Aneuploi-dy and overexpression of Ki-67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. Am J Gastroenterol 2009;104:2673-2680.
63. Chao DL, Sanchez CA, Galipeau PC, Blount PL, Paulson TG, et al: Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a longterm prospective study. Clin Cancer Res 2008;14:6988-6995.
64. Ooi A, Zen Y, Ninomiya I, Tajiri R, Suzuki S, et al: Gene amplification of ERBB2 and EGFR in adenocarcinoma in situ and intramuco-sal adenocarcinoma of Barrett's esophagus. Pathol Int 2010;60:466-471.
65. Binato M, Gurski RR, Fagundes RB, Meu-rer L, Edelweiss MI: P53 and Ki-67 overexpression in gastroesophageal reflux disease, Barrett's esophagus and adenocarcinoma sequence. Dis Esophagus 2009;22:588-595.
66. Zhang X, Yu C, Wilson K, Zhang HY, Melton SD, et al: Malignant transformation of non-neoplastic Barrett's epithelial cells through well-defined genetic manipulations. PLoS One 2010;5:pii, e13093.
67. Peng D, Belkhiri A, Hu T, Chaturvedi R, Asim M, et al: Glutathione peroxidase-7 protects against oxidative DNA damage in oesophageal cells. Gut (E-pub ahead of print).
68. Das KM, Kong Y, Bajpai M, Kulkarni D, Geng X, et al: Transformation of benign Barrett's epithelium by repeated acid and bile exposure over 65 weeks: a novel in vitro model. Int J Cancer 2011;128:274-282.
69. Karaman A, Binici DN, Kabalar ME, Koca T, Dursun H: Genomic instability in patients with Barrett's esophagus. Cancer Genet Cytogenet 2010;201:88-93.
70. Lai LA, Kostadinov R, Barrett MT, Peiffer DA, Pokholok D, et al: Deletion at fragile sites is a common and early event in Barrett's esophagus. Mol Cancer Res 2010;8: 1084-1094.
71. Vasavi M, Vedicherala B, Vattam KK, Ahuja YR, Hasan Q: Assessment of genetic damage in inflammatory, precancerous, and cancerous pathologies of the esophagus using the comet assay. Genet Test Mol Biomarkers 2010;14:477-482.
72. Dvorak K, Payne CM, Chavarria M, Ramsey L, Dvorakova B, et al: Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus. Gut 2007;56:763-771.
73. Feagins LA, Zhang HY, Zhang X, Hormi-Carver K, Thomas T, et al: Mechanisms of oxidant production in esophageal squamous cell and Barrett's cell lines. Am J Physiol Gastrointest Liver Physiol 2008;294: G411-G417.
74. Jolly AJ, Wild CP, Hardie LJ: Sodium deoxy-cholate causes nitric oxide mediated DNA damage in oesophageal cells. Free Radic Res 2009;43:234-240.
75. Jenkins GJ, Cronin J, Alhamdani A, Rawat N, D'Souza F, et al: The bile acid deoxycho-lic acid has a non-linear dose response for DNA damage and possibly NF-KB activation in oesophageal cells, with a mechanism of action involving ROS. Mutagenesis 2008;23: 399-405.
76. Cronin J, Williams L, McAdam E, Eltahir Z, Griffiths P, et al: The role of secondary bile acids in neoplastic development in the oesophagus. Biochem Soc Trans 2010;38: 337-342.
77. Clemons NJ, McColl KE, Fitzgerald RC: Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcino-genesis via distinct mechanisms. Gastroen-terology 2007;133:1198-1209.
78. Zhang HY, Hormi-Carver K, Zhang X, Spechler SJ, Souza RF: In benign Barrett's epithelial cells, acid exposure generates reactive oxygen species that cause DNA double-strand breaks. Cancer Res 2009;69: 9083-9089.
79. Clemons NJ, Shannon NB, Abeyratne LR, Walker CE, Saadi A, et al: Nitric oxide-mediated invasion in Barrett's high-grade dys-plasia and adenocarcinoma. Carcinogenesis 2010;31:1669-1675.
80. Hong J, Behar J, Wands J, Resnick M, Wang LJ, et al: Bile acid reflux contributes to development of esophageal adenocarcinoma via activation of phosphatidylinositol-specific phospholipase Cy2 and NADPH oxidase NOX5-S. Cancer Res 2010;70:1247-1255.
81. Hong J, Behar J, Wands J, Resnick M, Wang LJ, et al: Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. Gut 2010;59:170-180.
82. Terry P, Lagergren J, Ye W, Nyren O, Wolk A: Antioxidants and cancers of the esophagus and gastric cardia. Int J Cancer 2000;87: 750-754.
83. Danese S, Dejana E, Fiocchi C: Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation. J Immunol 2007;178:6017-6022.
84. Pober JS, Sessa WC: Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 2007;7:803-815.
85. Granger DN, Kubes P: The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol 1994; 55:662-675.
86. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, et al: Endothelial cells in physiology and in the pathophysiol-ogy of vascular disorders. Blood 1998;91: 3527-3561.
87. Couvelard A, Paraf F, Oratio V, Scoazec JY, Henin D, et al: Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEOF expression. J Pathol 2000; 192:14-18.
88. Mobius C, Stein HJ, Becker I, Feith M, Theisen J, et al: The 'angiogenic switch' in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Eur J Surg Oncol 2003;29:890-894.
89. Millikan KW, Mall JW, Myers JA, Hollinger EF, Doolas A, et al: Do angiogenesis and growth factor expression predict prognosis of esophageal cancer? Am Surg 2000;66: 401-406.
90. Saad RS, El-Oohary Y, Memari E, Liu YL, Silverman JF: Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum Pathol 2005;36:955-961.
91. Mobius C, Stein HJ, Spiess C, Becker I, Feith M, et al: COX2 expression, angiogenesis, proliferation and survival in Barrett's cancer. Eur J Surg Oncol 2005;31:755-759.
92. Von Rahden BH, Stein HJ, Puhringer F, Koch I, Langer R, et al: Coexpression of cyclooxy-genases (COX-1, COX-2) and vascular endo- thelial growth factors (VEOF-A, VEOF-C) in esophageal adenocarcinoma. Cancer Res 2005;65:5038-5044.
93. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311.
94. Moriyama N, Amano Y, Mishima Y, Okita K, Takahashi Y, et al: What is the clinical significance of stromal angiogenesis in Barrett's esophagus? J Oastroenterol Hepatol 2008; 23(suppl 2):S210-S215.
95. Rees JR, Lao-Sirieix P, Wong A, Fitzgerald RC: Treatment for Barrett's oesophagus. Cochrane Database Syst Rev 2010;1:CD004060.
96. Peters FT, Ganesh S, Kuipers EJ, Sluiter WJ, Klinkenberg-Knol EC, et al: Endoscopic regression of Barrett's oesophagus during omeprazole treatment: a randomised doubleblind study. Gut 1999;45:489-494.
97. Abu-Sneineh A, Tam W, Schoeman M, Fraser R, Ruszkiewicz AR, et al: The effects of highdose esomeprazole on gastric and oesopha-geal acid exposure and molecular markers in Barrett's oesophagus. Aliment Pharmacol Ther 2010;32:1023-1030.
98. Dent J: Barrett's esophagus: a historical perspective, an update on core practicalities and predictions on future evolutions of management. J Gastroenterol Hepatol 2011; 26(suppl 1):11-30.
99. Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, et al: Secondary che-moprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 2007;99:545-557.
100. Das D, Chilton AP, Jankowski JA: Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res 2009; 181:161-169.
101. Murphy SJ, Anderson LA, Ferguson HR, Johnston BT, Watson PR, et al: Dietary antioxidant and mineral intake in humans is associated with reduced risk of esophageal adenocarcinoma but not reflux esophagitis or Barrett's esophagus. J Nutr 2010;140: 1757-1763.